Small study found that 2 mg of melatonin taken at bedtime did not significantly decrease the mean number of nocturia episodes vs placebo.
Women presenting with lower urinary tract symptoms cluster into 4 distinct symptom groups, according to a recent study.
Recent studies provide insight into the epidemiology of the condition and its associated complications.
Bladder hydrodistention with fulguration of Hunner lesions reduced nocturia in IC patients with or without nocturnal polyuria.
Treatment appeared to reduce fall risk among older adults.
Study confirms associations between nocturia and older age, female sex, overactive bladder, and diabetes.
Men experiencing 3 or more nocturia episodes per night had a 43% increased mortality risk in adjusted analyses.
In a study, only 5% of nocturia and nocturnal polyuria were prescribed oral desmopressin.
Clinicians tend to focus on the number of voids, but patients worry more about interrupted sleep.
Rather intermittent oxygen desaturation was associated with a 3% greater likelihood of nocturia.
In clinical trials, the combination of Myrbetriq + solifenacin succinate was associated with greater improvements in the number of incontinence episodes per 24 hours (primary endpoint), the number of micturations per 24 hours (primary endpoint), and the volume voided per micturation (secondary endpoint) compared to placebo or to individual active components.
Thicker bladder wall and a tower-shaped curve on uroflowmetry are associated with shorter healing periods among pediatric patients with overactive bladder.
More patients taking desmopressin decreased their nightly voiding episodes by half or more.
Clinicians' choice of treatment highly correlated with a diagnosis based on urodynamic studies.
At least half of women using tibial nerve stimulation or pelvic floor muscle training experienced fewer night awakenings, according to a new study.
Metabolic syndrome and smoking are associated with 2.5- and 1.7-fold increased odds of moderate or severe nocturia in men with BPH/LUTS.
In a study, men with sleep disorders were 23% and 27% more likely to report nocturia and daytime LUTS than men without sleep disorders.
At baseline, women reported an average of 3.9 urgency incontinence episodes per day and 1.3 episodes of nocturia per night.
In a 12-month study, men with prostate cancer treated with ADT reported more nocturia episodes than men with prostate cancer treated with prostatectomy alone and men with no history of cancer.
Methylene blue aids observation of the procedure and assessment of drug distribution.
Clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients.
Onabotulinumtoxin A successfully reduced urinary frequency and urgency, but not urgency urinary incontinence episodes.
Pharmacologic properties of oxybutynin may cause significant cognitive side effects in elderly persons.
Treatment discontinuation rate is lower than that of traditional antimuscarinics, study finds.
Only a quarter of men receiving injections of BoNT-A comply with the treatment long-term.
Prospective study reveals a 1-year surgical intervention rate of 13%.
Consistent mean reductions in urinary incontinence; durable improvements in quality of life.
Reoperation rate for transvaginal mesh prolapse surgery is 4%.
De novo OAB — defined as urgency with or without frequency and nocturia — developed in some patients.
These same patients, however, had less intense detrusor overactivity, urodynamic evaluation revealed.
Renal and Urology News Articles
- FDA Recalls Drugs Containing Active Ingredient Valsartan
- Correcting Metabolic Acidosis May Preserve Muscle Mass
- Infection Risk Lower in Dialysis Patients With High, Normal Vitamin D
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)